Insider Selling: Pulmonx Co. (NASDAQ:LUNG) Director Sells 20,000 Shares of Stock

Pulmonx Co. (NASDAQ:LUNG) Director Glendon E. French III sold 20,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $6.63, for a total value of $132,600.00. Following the sale, the director now directly owns 1,071,974 shares of the company’s stock, valued at approximately $7,107,187.62. This trade represents a 1.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Pulmonx Price Performance

LUNG stock traded down $0.15 during trading on Tuesday, hitting $6.46. 105,251 shares of the company’s stock traded hands, compared to its average volume of 386,093. Pulmonx Co. has a 52 week low of $5.46 and a 52 week high of $14.84. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70. The business has a fifty day simple moving average of $7.00 and a 200 day simple moving average of $7.08. The stock has a market capitalization of $255.11 million, a price-to-earnings ratio of -4.39 and a beta of 0.68.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. During the same quarter last year, the business earned ($0.39) earnings per share. As a group, research analysts expect that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LUNG shares. Wells Fargo & Company dropped their price objective on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, August 1st. Stifel Nicolaus lowered their price objective on Pulmonx from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. Finally, Canaccord Genuity Group raised their price objective on Pulmonx from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $14.67.

Institutional Investors Weigh In On Pulmonx

Institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its holdings in Pulmonx by 4.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock valued at $332,000 after buying an additional 1,633 shares in the last quarter. Barclays PLC lifted its holdings in Pulmonx by 1.8% during the 3rd quarter. Barclays PLC now owns 94,109 shares of the company’s stock valued at $780,000 after buying an additional 1,679 shares in the last quarter. Sei Investments Co. lifted its holdings in Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock valued at $673,000 after buying an additional 1,800 shares in the last quarter. 272 Capital LP bought a new stake in Pulmonx during the 3rd quarter valued at about $25,000. Finally, nVerses Capital LLC bought a new stake in Pulmonx during the 3rd quarter valued at about $26,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.